Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Considerations for SGLT2 inhibitor use in post-transplantation diabetes

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been recommended for the treatment of patients with type 2 diabetes mellitus and cardiovascular disease, heart failure or chronic kidney disease. Findings from recent efficacy and safety trials of empagliflozin in kidney transplant recipients with post-transplantation diabetes are timely, given the elevated cardiovascular risk associated with solid organ transplantation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jenssen, T. & Hartmann, A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019).

    Article  Google Scholar 

  2. DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017).

    Article  CAS  Google Scholar 

  3. Schwaiger, E. et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am. J. Transplant. 19, 907–919 (2019).

    Article  CAS  Google Scholar 

  4. Halden, T. A. S. et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42, 1067–1074 (2019).

    Article  Google Scholar 

  5. Handelsman, Y. et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of Sglt-2 inhibitors and diabetic ketoacidosis. Endocr. Pract. 22, 753–762 (2016).

    Article  Google Scholar 

  6. Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61, 2461–2498 (2018).

    Article  Google Scholar 

Download references

Acknowledgements

The Empa-Renal Tx study from Oslo, Norway, was initiated and funded by the investigators and supported by grants from the South-Eastern Norway Regional Health Authority, the Norwegian Diabetes Association and Oslo Diabetes Research Centre. This study was supported by an unrestricted grant from Boehringer Ingelheim, Norway.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Manfred Hecking or Trond Jenssen.

Ethics declarations

Competing interests

T.J. has received lecture honoraria from Boehringer Ingelheim, AstraZeneca and Merck Sharp & Dohme. M.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hecking, M., Jenssen, T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 15, 525–526 (2019). https://doi.org/10.1038/s41581-019-0173-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-019-0173-0

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing